Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Other financing activities (2018 - 2022)

Historic Other financing activities for AdaptHealth (AHCO) over the last 5 years, with Q3 2022 value amounting to $808000.0.

  • AdaptHealth's Other financing activities fell 9275.08% to $808000.0 in Q3 2022 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $6.4 million for FY2024, which is N/A changed from last year.
  • AdaptHealth's Other financing activities amounted to $808000.0 in Q3 2022, which was down 9275.08% from $613000.0 recorded in Q2 2022.
  • In the past 5 years, AdaptHealth's Other financing activities registered a high of $16.1 million during Q1 2021, and its lowest value of -$2.3 million during Q4 2018.
  • Over the past 5 years, AdaptHealth's median Other financing activities value was $1.3 million (recorded in 2021), while the average stood at $4.3 million.
  • Per our database at Business Quant, AdaptHealth's Other financing activities soared by 8074.6% in 2019 and then tumbled by 9275.08% in 2022.
  • Over the past 5 years, AdaptHealth's Other financing activities (Quarter) stood at -$2.3 million in 2018, then surged by 100.01% to $247.0 in 2019, then skyrocketed by 68725.91% to $170000.0 in 2020, then soared by 6456.47% to $11.1 million in 2021, then crashed by 92.75% to $808000.0 in 2022.
  • Its Other financing activities stands at $808000.0 for Q3 2022, versus $613000.0 for Q2 2022 and $11.1 million for Q3 2021.